Ascendis Pharma A/S ADR ASND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ASND is a good fit for your portfolio.
News
-
Ascendis Pharma Says FDA Extending Review Period for NDA
-
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
-
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
-
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
-
Ascendis Pharma Reports First Quarter 2024 Financial Results
-
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
-
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
-
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
Trading Information
- Previous Close Price
- $124.82
- Day Range
- $123.69–128.25
- 52-Week Range
- $83.75–161.00
- Bid/Ask
- $49.62 / $133.00
- Market Cap
- $7.02 Bil
- Volume/Avg
- 998,212 / 345,951
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.74
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 879
- Website
- https://www.ascendispharma.com
Valuation
Metric
|
ASND
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 19.74 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ASND
|
---|---|
Quick Ratio | 0.49 |
Current Ratio | 0.83 |
Interest Coverage | −2.99 |
Quick Ratio
ASND
Profitability
Metric
|
ASND
|
---|---|
Return on Assets (Normalized) | −52.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −61.61% |
Return on Assets
ASND
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rzytkbmjj | Slhn | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fxzzzkv | Pldjt | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Htclmpnln | Pgscwf | $107.6 Bil | |
MRNA
| Moderna Inc | Xqxbmyzsf | Bzbzp | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Pxlcfxgk | Kjvm | $22.2 Bil | |
ARGX
| argenx SE ADR | Qqkwmnpkz | Xhmjg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cktjyhwz | Wmvnxgh | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qmvbrymdf | Ftdpwnn | $15.1 Bil | |
INCY
| Incyte Corp | Xxbphrm | Yvdlgl | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yvhvytpstq | Tmyldh | $12.7 Bil |